MiMedx Group, Inc.

NasdaqCM:MDXG Stock Report

Market Cap: US$1.3b

MiMedx Group Management

Management criteria checks 2/4

MiMedx Group's CEO is Joe Capper, appointed in Jan 2023, has a tenure of 2.08 years. total yearly compensation is $20.76M, comprised of 3.3% salary and 96.7% bonuses, including company stock and options. directly owns 0.068% of the company’s shares, worth $869.97K. The average tenure of the management team and the board of directors is 2.3 years and 4.4 years respectively.

Key information

Joe Capper

Chief executive officer

US$20.8m

Total compensation

CEO salary percentage3.3%
CEO tenure2.1yrs
CEO ownership0.07%
Management average tenure2.3yrs
Board average tenure4.4yrs

Recent management updates

Recent updates

We Think MiMedx Group (NASDAQ:MDXG) Can Manage Its Debt With Ease

Dec 23
We Think MiMedx Group (NASDAQ:MDXG) Can Manage Its Debt With Ease

We Ran A Stock Scan For Earnings Growth And MiMedx Group (NASDAQ:MDXG) Passed With Ease

Nov 21
We Ran A Stock Scan For Earnings Growth And MiMedx Group (NASDAQ:MDXG) Passed With Ease

There's No Escaping MiMedx Group, Inc.'s (NASDAQ:MDXG) Muted Earnings Despite A 27% Share Price Rise

Nov 06
There's No Escaping MiMedx Group, Inc.'s (NASDAQ:MDXG) Muted Earnings Despite A 27% Share Price Rise

MiMedx Group, Inc.'s (NASDAQ:MDXG) Shares Bounce 27% But Its Business Still Trails The Industry

May 21
MiMedx Group, Inc.'s (NASDAQ:MDXG) Shares Bounce 27% But Its Business Still Trails The Industry

We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt

May 14
We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt

Improved Revenues Required Before MiMedx Group, Inc. (NASDAQ:MDXG) Shares Find Their Feet

Mar 27
Improved Revenues Required Before MiMedx Group, Inc. (NASDAQ:MDXG) Shares Find Their Feet

We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt

Jan 05
We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt

MiMedx Group, Inc. (NASDAQ:MDXG) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Dec 18
MiMedx Group, Inc. (NASDAQ:MDXG) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Is MiMedx Group (NASDAQ:MDXG) Using Debt In A Risky Way?

Aug 08
Is MiMedx Group (NASDAQ:MDXG) Using Debt In A Risky Way?

Does MiMedx Group (NASDAQ:MDXG) Have A Healthy Balance Sheet?

Apr 22
Does MiMedx Group (NASDAQ:MDXG) Have A Healthy Balance Sheet?

Health Check: How Prudently Does MiMedx Group (NASDAQ:MDXG) Use Debt?

Dec 20
Health Check: How Prudently Does MiMedx Group (NASDAQ:MDXG) Use Debt?

MiMedx gets Japanese reimbursement approval for its tissue allograft EPIFIX

Sep 12

MiMedx Group expects AWC full-year sales in low end of 11%-14% growth range

Sep 06

CEO Compensation Analysis

How has Joe Capper's remuneration changed compared to MiMedx Group's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

US$79m

Jun 30 2024n/an/a

US$79m

Mar 31 2024n/an/a

US$68m

Dec 31 2023US$21mUS$678k

US$56m

Compensation vs Market: Joe's total compensation ($USD20.76M) is above average for companies of similar size in the US market ($USD5.31M).

Compensation vs Earnings: Insufficient data to compare Joe's compensation with company performance.

CEO

Joe Capper (60 yo)

2.1yrs

Tenure

US$20,756,346

Compensation

Mr. Joseph H. Capper, also known as Joe, is an Independent Director at Anika Therapeutics, Inc since May 28, 2024. He serves as Chief Executive Officer and Director of MiMedx Group, Inc. since January 30,...

Leadership Team

NamePositionTenureCompensationOwnership
Joseph Capper
CEO & Director2.1yrsUS$20.76m0.068%
$ 870.0k
Douglas Rice
Chief Financial Officer1.6yrsUS$2.75m0.017%
$ 214.5k
William Hulse
General Counsel & Chief Administrative Officer5.2yrsUS$1.91m0.17%
$ 2.1m
Scott Turner
Senior Vice President of Operations & Procurement1.8yrsUS$619.46kno data
Matthew Notarianni
Head of Investor Relations2.3yrsno datano data
Mark Graves
Senior VP & Chief Compliance Officer1.8yrsno datano data
Hilary Dixon
Vice President of Investor Relations & Corporate Strategic Communicationsno datano datano data
Kate Surdez
Chief Human Resources Officer2.6yrsno datano data
David Mason
Chief Medical Officer6.2yrsno datano data
Robert Stein
President of Regenerative Medicine & Biologics Innovation4.5yrsUS$1.74mno data
Kim Moller
Chief Commercial Officerless than a yearno data0.057%
$ 732.0k
Rebeccah J. Brown
Vice President of Global Regulatory Affairs11.8yrsUS$198.47kno data

2.3yrs

Average Tenure

58.5yo

Average Age

Experienced Management: MDXG's management team is considered experienced (2.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Joseph Capper
CEO & Director2.1yrsUS$20.76m0.068%
$ 870.0k
Martin Sutter
Independent Preferred Director4.6yrsno data0.00034%
$ 4.3k
James Bierman
Independent Director5.7yrsUS$278.43k0.11%
$ 1.4m
William Hawkins
Independent Preferred Director4.6yrsUS$264.50k0.10%
$ 1.3m
James Andrews
Member of Medical Advisory Boardno datano datano data
Anthony Atala
Member of Regenerative Medicine Scientific Advisory Board2.6yrsno datano data
Thomas Zdeblick
Member of Medical Advisory Boardno datano datano data
Cato Laurencin
Independent Director4.3yrsUS$282.14k0.089%
$ 1.1m
K. Newton
Independent Director5.7yrsUS$1.35m0.25%
$ 3.1m
Robert Guldberg
Member of Regenerative Medicine Scientific Advisory Boardno datano datano data
Glenn Gaston
Member of Medical Advisory Boardno datano datano data
Kris Alden
Member of Regenerative Medicine Scientific Advisory Board2.6yrsno datano data

4.4yrs

Average Tenure

67.5yo

Average Age

Experienced Board: MDXG's board of directors are considered experienced (4.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/02 03:23
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

MiMedx Group, Inc. is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason WittesBrean Capital
William PlovanicCanaccord Genuity
Ross OsbornCantor Fitzgerald & Co.